233 related articles for article (PubMed ID: 21850367)
21. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
22. Effects of Celastrol on growth inhibition of U937 leukemia cells through the regulation of the Notch1/NF-kappaB signaling pathway in vitro.
Wang XN; Wu Q; Yang X; Zhang LS; Wu YP; Lu C
Chin J Cancer; 2010 Apr; 29(4):385-90. PubMed ID: 20346213
[TBL] [Abstract][Full Text] [Related]
23. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
24. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro.
Qin Y; Sun CY; Lu FR; Shu XR; Yang D; Chen L; She XM; Gregg NM; Guo T; Hu Y
Leuk Res; 2012 Apr; 36(4):514-20. PubMed ID: 22226224
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
Zheng L; Fu Y; Zhuang L; Gai R; Ma J; Lou J; Zhu H; He Q; Yang B
Int J Cancer; 2014 Oct; 135(7):1721-32. PubMed ID: 24615207
[TBL] [Abstract][Full Text] [Related]
26. Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma.
Zhao Y; Bai D; Du J; Ren H; Zhang Z; Jiang C; Lu N
Cell Biol Toxicol; 2021 Feb; 37(1):97-111. PubMed ID: 33126266
[TBL] [Abstract][Full Text] [Related]
27. Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway.
Lin FZ; Wang SC; Hsi YT; Lo YS; Lin CC; Chuang YC; Lin SH; Hsieh MJ; Chen MK
Phytomedicine; 2019 Feb; 54():1-8. PubMed ID: 30668359
[TBL] [Abstract][Full Text] [Related]
28. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Dai Y; Desano J; Tang W; Meng X; Meng Y; Burstein E; Lawrence TS; Xu L
PLoS One; 2010 Dec; 5(12):e14153. PubMed ID: 21170316
[TBL] [Abstract][Full Text] [Related]
29. Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway.
Takeda T; Tsubaki M; Kino T; Kawamura A; Isoyama S; Itoh T; Imano M; Tanabe G; Muraoka O; Matsuda H; Satou T; Nishida S
Int J Oncol; 2016 Jun; 48(6):2704-12. PubMed ID: 27035859
[TBL] [Abstract][Full Text] [Related]
30. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways.
Kannaiyan R; Manu KA; Chen L; Li F; Rajendran P; Subramaniam A; Lam P; Kumar AP; Sethi G
Apoptosis; 2011 Oct; 16(10):1028-41. PubMed ID: 21786165
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
[TBL] [Abstract][Full Text] [Related]
32. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study.
Li HY; Zhang J; Sun LL; Li BH; Gao HL; Xie T; Zhang N; Ye ZM
Cell Death Dis; 2015 Jan; 6(1):e1604. PubMed ID: 25611379
[TBL] [Abstract][Full Text] [Related]
33. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
34. Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-κB signaling pathway.
Gao H; Wang J
Mol Med Rep; 2016 Feb; 13(2):1827-32. PubMed ID: 26707811
[TBL] [Abstract][Full Text] [Related]
35. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Fan XX; Li N; Wu JL; Zhou YL; He JX; Liu L; Leung EL
Molecules; 2014 Mar; 19(3):3508-22. PubMed ID: 24662070
[TBL] [Abstract][Full Text] [Related]
36. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways.
Mou H; Zheng Y; Zhao P; Bao H; Fang W; Xu N
Toxicol In Vitro; 2011 Aug; 25(5):1027-32. PubMed ID: 21466843
[TBL] [Abstract][Full Text] [Related]
37. Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.
Zhou LL; Lin ZX; Fung KP; Cheng CH; Che CT; Zhao M; Wu SH; Zuo Z
Eur J Pharmacol; 2011 Nov; 670(2-3):399-408. PubMed ID: 21951963
[TBL] [Abstract][Full Text] [Related]
38. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.
Meinel FG; Mandl-Weber S; Baumann P; Leban J; Schmidmaier R
Mol Cancer Ther; 2010 Feb; 9(2):300-10. PubMed ID: 20124446
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid.
Lee JH; Koo TH; Yoon H; Jung HS; Jin HZ; Lee K; Hong YS; Lee JJ
Biochem Pharmacol; 2006 Nov; 72(10):1311-21. PubMed ID: 16984800
[TBL] [Abstract][Full Text] [Related]
40. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma.
Kozanoglu I; Yandim MK; Cincin ZB; Ozdogu H; Cakmakoglu B; Baran Y
J Cancer Res Clin Oncol; 2013 Feb; 139(2):327-35. PubMed ID: 23080133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
